Allorion Raises $50 Million for Oncology/Autoimmune Precision Medicines
publication date: Mar 10, 2023
Allorion Therapeutics, a Guangzhou-Boston biotech, completed a $50 million Series B financing to advance its next-gen precision medicines for oncology and autoimmune diseases. The company said it would use the proceeds to fund Phase I/II clinical trials in both China and the US for its two lead molecules and identify clinical candidates for additional programs. The B round was co-led by INCE Capital and Qiming Venture Partners, with participation from TF Capital, Long River Investment, 3SBio, Octagon Capital and Elikon Venture. Since its 2020 start, Allorion has raised over $100 million. More details....
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.